XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended
Jun. 30, 2022
USD ($)
trial
segment
shares
Jun. 30, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of successful clinical trials | trial 5  
Number of operating segments | segment 1  
Number of reporting segments | segment 1  
Amortization of operating lease right-of-use assets $ 460,000 $ 403,000
Cash, cash equivalents and marketable securities $ 358,700,000  
Sumitomo Pharma, Co., Ltd. | Majority Shareholder    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of shares owned (in shares) | shares 50,041,181  
Ownership percentage 52.30%  
Sumitomo Pharma, Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan | Majority Shareholder    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Available borrowing capacity $ 41,300,000  
Pfizer    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Outstanding payment from milestones achieved 3,600,000,000  
Richter    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Outstanding payment from milestones achieved $ 122,500,000